8-K: Tivic Health Appoints Michael Handley as COO and President of Tivic Biopharma

Michael Handley, former CEO of Statera Biopharma, joins Tivic Health to lead the newly formed Tivic Biopharma division and serve as Chief Operating Officer.

Summary

• Tivic Health Systems, Inc. has appointed Michael Handley as Chief Operating Officer and President of its Tivic Biopharma division, effective February 18, 2025.
• Handley's responsibilities include building the Tivic Biopharma team, advancing the late-stage product candidate Entolimod, and directing pipeline development.
• He will receive a base salary of $300,000 per annum, eligibility for an annual incentive bonus of up to 35% of his base salary, and a grant of 600,000 restricted stock units vesting over four years.
• The appointment is connected to the exclusive license agreement between Tivic Health and Statera Biopharma, Inc. disclosed on February 12, 2025.
• Handley's employment is at will, and separation benefits are contingent upon certain conditions, including the execution of a release of claims agreement.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting the appointment of an experienced executive and the company's expansion into a new therapeutic area. However, the forward-looking statements and inherent risks associated with drug development temper the overall sentiment.

Positives

• Michael Handley brings over two decades of experience in drug/device commercialization, regulatory/clinical affairs, and operations.
• Handley has a proven track record of successfully leading or assisting in the global commercialization of 17 drugs and devices.
• The addition of Handley is expected to facilitate Tivic Health's expansion into biopharmaceutical capabilities and advance its therapeutics pipeline.
• The licensing of Entolimod provides Tivic Health with a late-stage product candidate with potential in radiation toxicity and immune system dysregulation.

Negatives

• Handley's employment is at will, meaning either he or the company can terminate his employment at any time.
• He will not be eligible to receive any incentive bonus if his employment terminates for any reason before December 31 of any given year.
• Separation benefits are contingent upon signing a release of claims agreement, which must become effective and irrevocable no later than the 60th day following an involuntary termination.

Risks

• The success of Tivic Health's expansion into biopharmaceuticals depends on the successful development and commercialization of Entolimod.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to achieve its goals is subject to market conditions, macroeconomic factors, and unexpected costs or expenses.

Future Outlook

Tivic Health aims to build shareholder value by developing both non-invasive bioelectronic vagus nerve stimulation and drug therapeutics, with a focus on advancing Entolimod towards potential commercialization and expanding its biopharma pipeline.

Management Comments

• Jennifer Ernst, Tivic Health Chief Executive Officer, stated that Mike brings to Tivic a rare blend of device and pharmaceutical background, as well as proven operational, business and scientific experience that sets Tivic up for a smooth and successful expansion into drug development.
• Michael Handley stated that this is an exciting and critical time at Tivic Health, and he is thrilled to join the Tivic leadership team to continue the essential work of advancing Entolimod towards potential commercialization.

Industry Context

Tivic Health's move to appoint a seasoned biopharma executive and license a late-stage drug candidate signals a strategic shift towards diversifying its therapeutic offerings and expanding into the biopharmaceutical space, complementing its existing bioelectronic device business.

Comparison to Industry Standards

• Michael Handley's compensation package, including a $300,000 base salary and potential 35% bonus, is within the typical range for a COO and President of a division in a company of Tivic Health's size and stage.
• The grant of 600,000 restricted stock units is a common inducement for attracting executive talent, aligning their interests with the company's long-term success.
• The vesting schedule of the RSUs, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, is a standard vesting arrangement.
• Tivic Health's licensing of Entolimod from Statera Biopharma is similar to other pharmaceutical companies acquiring or licensing promising drug candidates to expand their pipelines.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the company's expansion into biopharmaceuticals and the potential commercialization of Entolimod.
• Employees in the newly formed Tivic Biopharma division will have opportunities to work on advancing a late-stage drug candidate.
• The company's success in developing and commercializing new therapeutics could improve patient outcomes and address unmet medical needs.

Next Steps

• Build and lead Tivic's Biopharma team.
• Advance Tivic's recently licensed, late-stage product candidate, Entolimod through manufacturing validation, regulatory approval processes and commercialization.
• Direct pipeline development activity.

Key Dates

Keywords

Tivic Health, Michael Handley, Chief Operating Officer, President, Tivic Biopharma, Entolimod, Biopharma, Executive Appointment, Restricted Stock Units, Nasdaq